|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
Infective endocarditis is a life-threatening infectious syndrome that is associated with significant morbidity, mortality and cost. As an educational package focusing on this important disease state, this activity includes a recorded lecture and a separate supplemental reading created by the faculty. The recorded lecture outlines fundamental principles of endocarditis management (epidemiology, diagnosis, risk factors, and treatment recommendations) according to the 2015 American Heart Association guidelines. While guideline recommendations are considered the standard of care, there are certain situations where guideline-based treatment options may not be ideal or effective. Therefore, the second component of this activity is a supplemental reading intended to build upon the core content presented in the recorded lecture. This supplemental reading specifically aims to address contemporary and/or advanced issues surrounding the management of bacterial endocarditis that have become increasingly recognized since the 2015 American Heart Association guidelines were published. These contemporary issues include the use of daptomycin plus ceftaroline combination therapy, the role of novel lipoglycopeptides in managing infective endocarditis, and the role of oral antimicrobial therapy based on the POET trial and other recent data.
The target audience for this activity includes pharmacists and board-certified infectious diseases pharmacists (BCIDPs). At the completion of this activity, the participant will be able to:
- Identify data that examines the utility of adding ceftaroline to daptomycin for the treatment of infective endocarditis (IE).
- Discuss literature associated with the use of lipoglycopeptides for the treatment of IE.
- Review currently available data to determine if oral antimicrobial therapy is an appropriate treatment option for IE.
Jessica Robinson, PharmD, BCPS, BCIDP
Associate Professor and Infectious Diseases Pharmacy Specialist
University of Charleston School of Pharmacy
Release Date: April 14, 2021
Expiration Date: April 14, 2022
This activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-128-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 1.75 contact hour (0.175 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 04/14/2021 for this activity and is available for one year from this date.
Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the joint program offered by the Society of Infectious Diseases Pharmacists (SIDP), the American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Jessica Robinson has no conflict of interest to report.
This activity is provided by ProCE, LLC and SIDP.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.